5-Methoxycarbonyl-imidazol-4-carbonsaeure | 3304-71-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-Methoxycarbonyl-imidazol-4-carbonsaeure
• 英文别名: 1H-imidazole-4,5-dicarboxylic acid monomethyl ester；5-methoxycarbonyl-1H-imidazole-4-carboxylic acid
• CAS: 3304-71-0
• 化学式: C₆H₆N₂O₄
• 分子量: 170.125
• InChiKey: IXYRNOVMYKGRAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  92.3
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
  申请人：Eckhardt Matthias

  公开号：US20050203095A1

  公开（公告）日：2005-09-15

  The invention relates to substituted imidazopyridazinediones of general formula wherein R 1 and R 4 are defined as in claim 1, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

  这项发明涉及一般式的取代咪唑吡啶二酮，其中R1和R4如权利要求1中定义，其互变异构体、对映体、非对映体、其混合物及其盐具有有价值的药理特性，特别是对酶二肽基肽酶-IV（DPP-IV）活性的抑制作用。
• CEPHEM COMPOUND HAVING PYRIDINIUM GROUP
  申请人：Nishitani Yasuhiro

  公开号：US20140114060A1

  公开（公告）日：2014-04-24

  The present invention provides a novel compound which has a broad antibacterial spectrum and particularly exhibits a high antibacterial activity on β-lactamase-producing gram-negative bacteria. Specifically provided are: a compound represented by formula (I) wherein the meaning of each symbol is as defined in the description, an amino-group-protected form of a type of the compound which has the amino group on a ring in a position-7 side chain, or a pharmaceutically acceptable salt of the compound or the amino-group-protected form; and a pharmaceutical composition containing the compound, the amino-group-protected form or the pharmaceutically acceptable salt.

  本发明提供了一种新型化合物，具有广泛的抗菌谱，特别对产β-内酰胺酶的革兰氏阴性细菌表现出高抗菌活性。具体提供的是：一种由式(I)表示的化合物，其中每个符号的含义如描述中定义的那样，一种在环上具有氨基团的化合物的保护形式，该化合物在位置-7侧链上具有氨基团，或者化合物或氨基团保护形式的药用可接受盐；以及含有该化合物、氨基团保护形式或药用可接受盐的药物组合物。
• CEPHEM COMPOUND
  申请人：SHIONOGI & CO., LTD.

  公开号：US20150344502A1

  公开（公告）日：2015-12-03

  A compound of the formula: wherein, W is —CH2 − etc.; U is —S − etc.; R 1 is substituted or unsubstituted carbocyclyl etc.; R 2A and R 2B is a) or b) described in the specification; R 3 is a hydrogen atom etc.; R 11 is carboxylate anion (—COO − ) etc.; L is substituted or unsubstituted lower alkylene etc., E is a substituted or unsubstituted divalent group containing quaternary ammonium ion; G is a single bond etc.; D is —C(═O)—C(═O)—NR 6 — etc.; R 10 1) to 3) described in specification; or an amino-protected compound when the amino group is present on the ring in the 7-side chain, or a pharmaceutically acceptable salt thereof.

  公式为：其中，W为—CH2−等；U为—S−等；R1为取代或未取代的碳环等；R2A和R2B为规范中描述的a)或b)；R3为氢原子等；R11为羧酸根离子(—COO−)等；L为取代或未取代的较低烷基等；E为含季铵离子的取代或未取代的双价基团；G为单键等；D为—C(═O)—C(═O)—NR6—等；R10为规范中描述的1)至3)；或者是7-侧链环上存在氨基时的氨基保护化合物，或其药用可接受盐。
• Ring expanded nucleosides and nucleotides
  申请人：——

  公开号：US20040077564A1

  公开（公告）日：2004-04-22

  The present invention relates to compositions comprising analogues of purine nucleosides containing a ring-expanded (“fat”) heterocyclic ring, in place of purine, and an unmodified or modified sugar residue, pharmaceutically acceptable derivatives of such compositions, as well as methods of use thereof. In particular, these compositions may be utilized in the treatment of certain cancers, bacterial, fungal, parasitic, and viral infections, including, but not limited to, Acquired Immunodeficiency Syndrome (AIDS), hepatitis, Epstein-Barr and cytomegalovirus.

  本发明涉及含有环扩张（“肥胖”）杂环环代替嘌呤的嘌呤核苷类似物和未经改性或改性的糖残基的组合物，以及这些组合物的药学上可接受的衍生物，以及其使用方法。特别地，这些组合物可用于治疗某些癌症、细菌、真菌、寄生虫和病毒感染，包括但不限于获得性免疫缺陷综合症（AIDS）、肝炎、EB病毒和巨细胞病毒。
• Phosphonate analogs of HIV integrase inhibitor compounds
  申请人：Cai R. Zhenhong

  公开号：US20060116356A1

  公开（公告）日：2006-06-01

  Novel HIV integrase inhibitor compounds having at least one phosphonate group, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.

  本发明揭示了至少具有一个膦酸酯基团的新型HIV整合酶抑制剂化合物，其保护中间体以及用于抑制HIV整合酶的方法。